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Introduction. Endoscopic resection (ER) exceeding ≥75% of the esophageal circumference is accompanied with a high stricture risk
regardless of the resection method. The ideal strategy for stricture prevention is not well defined today. Different approaches have
been reported but data are limited to the resection of squamous cell neoplasia. The aim of this study was to assess the efficacy of an
individualized oral steroid regimen to prevent strictures after extensive ER in neoplastic Barrett’s esophagus (NBE).Materials and
Methods. Over a 50-month period, endoscopic submucosal dissection (ESD) was performed in 193 patients with NBE. 23 patients
with resections exceeding 75% of the circumference were included. 19 resection ulcers were noncircumferential (NCR) while 4 were
circumferential (CR). Stricture prevention was performed using oral prednisolone starting with a daily dose of 50mg and standard
tapering over 8 weeks (50/40/30/25/20/15/10/5mg). Tapering was individualized according to the ulcer healing process (assessed
endoscopically in the first tapering period and before stopping the steroids). Data were analyzed retrospectively. Results. Stricture
rates were 5.3% (1/19) for NCR and 100% (4/4) for CR (p < 0 001). The only stricture in the NCR group was seen in a patient who
had stopped steroids without any reason after few days. 12/19 patients received standard tapering over 8 weeks (63.1%). According
to the individual ulcer healing, treatment was prolonged to 9-10 weeks in 4/19 (21.1%) and shortened to 7 weeks in another 2/19
(10.5%). After CR, all patients needed endoscopic balloon dilatation (median 6.5 sessions; range 3-14 sessions for 8-40 weeks). Side
effects of the steroid therapy were not noted. Conclusion. Oral prednisolone therapy with an endoscopy-based individualized
tapering regimen is effective in avoiding strictures after NCR of Barrett’s neoplasia. After CR, the stricture risk is not sufficiently
decreased. CR should be restricted to circumferential neoplasia which is a very rare scenario in neoplastic BE.
1. Introduction
The incidence of esophageal adenocarcinoma (EAC) is rising
in Western countries [1]. Progress in endoscopic technology
and surveillance programs for patients with Barrett’s esopha-
gus (BE) have improved the diagnosis of EAC in early stages
allowing endoscopic resection (ER) as a curative treatment
option. Endoscopic mucosal resection (EMR) of visible neo-
plastic lesions and additional ablation of the residual Barrett’s
are the standard treatment of neoplastic BE today. In selected
neoplasia (lesion diameter exceeding 15mm, poor-lifting
lesions, and lesions at risk for submucosal invasion), endo-
scopic submucosal dissection (ESD) can be considered as a
treatment option in order to achieve R0 resection and to
improve histopathological assessment of R0 resection [2].
When ER is performed circumferentially or the resection
area exceeds three quarters of the circumference, a substan-
tial stricture risk has been reported for EMR (49.7-88%)
and also for ESD (60.0%) in BE [3–5]. Different strategies
have been introduced to prevent stricture development
(balloon dilatation, stenting, local or systemic steroid therapy
in fixed-dosage regimens, and tissue-shielding techniques).
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These techniques have been shown to reduce but not to
eliminate the stricture risk, and the ideal strategy for stricture
prevention remains undefined. In our previous study on ESD
for neoplastic BE and early esophageal squamous cell cancers
(SCCs), we performed prophylactic endoscopic balloon dila-
tation (EBD) in the first study period and used a fixed-dose
regimen of oral steroids in the second. In the dilatation
group, a high number of EBD sessions (mean 8.2) were
needed to prevent strictures and perforation was noted
during EBD in one patient. In the steroid group, 62.5% devel-
oped a stricture during the steroid tapering period and EBD
was required also in these patients [6]. Data on stricture
prevention, published mainly by Asian authors, are
restricted to ER of SCCs due to the rareness of Barrett’s
esophagus in Asia. The aim of this study was to evaluate
the efficacy of a modified stricture prevention strategy after
extensive ER in neoplastic BE (oral steroid treatment regi-
men with endoscopy-based control of dosage and duration).
2. Patients and Methods
The study was conducted as a single-center uncontrolled
study in a German referral center (Department of Gastroen-
terology, Klinikum Augsburg, Germany). All patients who
underwent ESD of Barrett’s neoplasia from May 2014 to July
2018 were screened. All patients had given written informed
consent after receiving detailed information about the ESD
procedure and alternative treatment options (EMR, surgery).
Data were analyzed retrospectively. The study was approved
by the Institutional Review Board of Klinikum Augsburg,
Germany (IRB number BKF-A-2018-24).
2.1. Inclusion Criteria. Inclusion criteria are as follows:
(i) ESD in neoplastic BE
(ii) Resection ulcer ≥ 75% of the esophageal circumference
(a) Noncircumferential resection (NCR)
(b) Resection involving the entire circumference (CR)
(iii) Stricture prevention performed with oral steroids
2.2. Exclusion Criteria. Exclusion criteria are as follows:
(i) Stricture prevention with other treatment regimens
than oral steroids (local steroid injection into the
resection ulcer, combinationof oral and local steroids)
(ii) Patients receiving steroid therapy for other
indications
2.3. Study End Points. The primary end point was the stric-
ture rate after ESD. Secondary end points were procedural
characteristics (procedure time, R0 resection rate, curative
resection rate, and other complications than stricture).
2.4. ESD Procedure. All patients had been referred for ER,
and biopsies had shown high-grade dysplasia or EAC. Video
endoscopy with white light and narrow band imaging was
performed with a video gastroscope (GIF-HQ190; Olympus
Medical Systems, Tokyo, Japan). When the lesion lateral
margin was unclear, chromoendoscopy with acetic acid and
indigo carmine was added. Lesions were classified according
to the Paris classification [7]. EUS was not performed
routinely. A transparent cap at the tip of the scope (D-201-
11804, Olympus) and insufflation with carbon dioxide were
used routinely. Resection margins were marked using the
tip of a hook knife (KD-620LR; Olympus). The standard
solution for submucosal injection was a mixture of saline,
epinephrine (1 : 100.000), glycerol (10%), and a slight amount
of indigo carmine. In cases with severe fibrosis, hyaluronic
acid (Sigmavisc™, Hyaltech Ltd., Livingston, UK) was
injected. A VIO 300D electrosurgical generator (ERBE
Elektromedizin, Tübingen, Germany) was used (spray coag
mode 25W for marking; endo cut I mode 60−80W for
cutting and spray coag mode 60W for coagulation during
dissection). Mucosal incision and submucosal dissection
were performed with the hook knife. ESD was performed
under general anesthesia. Patients stayed in the hospital for
48−96 hours after ESD. Routine control endoscopies were
not performed before discharge. Anticoagulants, except aspi-
rin, had been stopped before ESD and were restarted 5-7 days
after the procedure depending on endoscopist’s decision.
2.5. Histopathologic Workup. Intramucosal lesions were clas-
sified as low-grade dysplasia (LGD), high-grade dysplasia
(HGD), or mucosal cancer. Invasion depth, grading, and
the presence or absence of lymphovascular invasion were
described. Regarding their invasion depth, lesions were clas-
sified mucosal (pT1a) or submucosal (pT1b). Grading was
categorized into G1 (well differentiated), G2 (moderately dif-
ferentiated), and G3 (poorly differentiated). R0 or R1 was
diagnosed for the vertical margin (VM) and the horizontal
margin (HM). Curative resection was defined as R0 resection
of a well- or moderately differentiated intramucosal cancer
without lymphovascular invasion.
2.6. Complications. Stricture was defined as a complication
when it was impossible to pass the esophagus using a
standard gastroscope (e.g., GIF-HQ190; diameter 9.9mm).
Delayed bleeding was defined as when clinical bleeding signs
were observed after ESD (hematemesis, melena, and hemo-
globin drop > 2 g/dl). In these cases, endoscopic treatment
was performed. Perforation was defined as an endoscopic
view into the mediastinum or the peritoneal cavity.
2.7. Regimen for Stricture Prevention and Follow-Up. Based
on the results of our previous study and based on the pub-
lished literature on preventive steroid treatment, we devel-
oped a modified steroid-based regimen and used it from
2014 [6, 8–12]. Taking Asian data into account, we chose a
starting dose of 50mg prednisolone daily and tapered this
gradually over 8 weeks (50/40/30/25/20/15/10/5mg) result-
ing in a cumulative dose of 1365mg. Prednisolone was
started on the first day after ESD when the resection ulcer
2 Gastroenterology Research and Practice
exceeded three quarters of the esophageal circumference.
Extension of the resection ulcer was estimated at the end of
the ESD procedure. We performed a first control endoscopy
in the third week after ESD (days 15-22) under a daily pred-
nisolone dose of 30mg. Patients’ symptoms, the extent of
ulcer healing (reepithelialization from the ulcer margins),
and the presence of stricture were assessed. Reepithelializa-
tion was defined as rapid (RE) when it exceeded 50% of the
initial resection area. When patients denied dysphagia, the
steroid treatment was tapered according to the degree of ree-
pithelialization. When RE was noted, the next step of steroid
tapering was skipped. When reepithelialization was not
rapid, steroids were continued using the standard tapering
regimen. When passage with the gastroscope was possible
but patients reported any kind of dysphagia, the next step
of steroid tapering was delayed for one or two weeks. When
stricture had developed, EBD was started and continued
according to the endoscopist’s recommendation. In patients
without stricture, a second control endoscopy was recom-
mended in week eight. When complete healing of the ulcer
was seen, steroids were stopped. When small residual ulcers
(≤10mm) were diagnosed, completion of the steroid treat-
ment was recommended according to the standard tapering
regimen. When large ulcers (>10mm) were present, a daily
prednisolone dose of 5mg was recommended for another 1-2
weeks. The treatment algorithm is shown in Figure 1.
When patients reported dysphagia, endoscopy was per-
formed on demand at any time to rule out strictures. Acid
suppression with proton pump inhibitors (PPI) was
started at the latest on the day before ESD and was con-
tinued for three months in all patients (pantoprazole
40mg twice daily). When residual Barrett’s epithelium
was seen in the second control endoscopy, patients were
scheduled for ablative therapy later and PPI therapy was
continued until then.
2.8. Statistical Analysis. Calculations were performed using
the software package Sigma Plot 13.0 (Systat Software, San
Jose, USA). Numeric values were compared using the
Mann-Whitney test. For the comparison of categorical data,
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Figure 1: Regimen for stricture prevention (EBD: endoscopic balloon dilatation).
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3. Results
3.1. Patients and Lesion Characteristics. Over a 50-month
period, 193 ESD procedures were performed for neoplastic
BE. 27 resection ulcers exceeded ≥75% of the circumference
(13.7%). Three patients were excluded because they had
received additional intralesional triamcinolone injection dur-
ing the first study period. Another patient was excluded
because of permanent steroid treatment performed for rheu-
matoid arthritis. 23 patients who started the proposed stric-
ture prevention regimen were included for further analysis.
The reason for extensive ESD was a large neoplasia in 13
patients (56.5%) and multifocal visible lesions in another 10
patients (43.5%) (Table 1).
3.2. Procedure Characteristics. Table 2 shows the procedure
characteristics. Resections were NCR in 19 patients (82.6%)
and CR in another four (17.4%). 21 resections were judged
curative (91.3%). In two patients (G3 sm1 L1 Rx at the VM
and G3 sm1 L0 V0 R0, respectively), surgery was recom-
mended but both patients refused. Both patients remained
free of recurrence during follow-up of 40 months and 37
months, respectively.
3.3. Strictures. 23 patients started oral steroid therapy on the
day after ESD. Patients’ course is shown in Figure 2. One
patient stopped steroid treatment without reasons and with-
out notable side effects on the fourth day after ESD. He
refused a scheduled control endoscopy and presented with
a symptomatic stricture on day 27. Stricture was treated with
three sessions of EBD. 17/19 patients with NCR and all four
patients with CR underwent the recommended first control
endoscopy after 2-3 weeks. At that time, all patients with
CR had developed symptomatic strictures despite continued
daily prednisolone dose of 30-40mg. Repeated EBD was per-
formed (median 6.5 sessions; range 3-14 sessions for 8-40
weeks). The length of the resection ulcer was not significantly
different between the NCR and CR groups (median 42.5 vs.
50mm; p = 0 19). None of the patients who continued steroid
prophylaxis after NCR had developed a stricture at first con-
trol endoscopy, and steroids were tapered according to the
degree of reepithelialization of the ESD ulcer. In ten patients,
second control endoscopy was performed before stopping
the steroid therapy. In another eight patients, second control
endoscopy was not performed in time because of patient’s
refusal. In these patients, prednisolone was stopped accord-
ing to the standard tapering regimen. In summary, 12
patients received the standard prednisolone regimen over 8
weeks. Treatment duration was prolonged to nine weeks in
two patients and to ten weeks in another two. Decision to
delay the treatment was made after the first control endos-
copy in two and after the second control in the other two.
In two patients, treatment was shortened to seven weeks after
the first control endoscopy. The first control endoscopy was
delayed on days 23-27 in three patients. None of these
patients needed modification of the treatment. One patient
had refused any control endoscopy and completed the stan-
dard steroid regimen over 8 weeks without a stricture. In
summary, no stricture was seen in the NCR group when
Table 1: Patients and lesion characteristics.
n = 23
Clinical characteristics
Age, median (range) (years) 67 (45-84)
Sex, male/female, n 21/2
ASA grade, 1/2/3, n 8/12/3
Barrett’s extent
C (median, range) (cm) 2 (0-9)
M (median, range) (cm) 5 (2-10)
Hiatal hernia, n (%) 21 (91.3)
Lesion characteristics





Endoscopic estimation of neoplasia
Single lesion, n (%) 13 (56.5)
Estimated diameter of single lesion;
median (range), mm
40 (20-60)
Multifocal neoplasia (≥1 visible lesion), n (%) 10 (43.5%)
Pretreated lesions 0
Table 2: Procedure characteristics (∗R0 for neoplasia was defined as
R0 for cancer and high-grade dysplasia. ∗∗Rx resection was
diagnosed at the HM in one lesion and at the HM in another).
Procedure time, median (range) (minutes) 150 (75-300)
Resection rates,n(%)
En bloc resection 23 (100)
R status for neoplasia∗, R0/R1/Rx 21 (91.3)/0/2∗∗ (8.7)
R status for Barrett’s metaplasia, R0/R1/Rx 8 (34.8)/15 (65.2)/0
Resection ulcer
75-89% of the circumference, n (%) 12 (52.2)
90-99% of the circumference, n (%) 7 (30.4)
100% of the circumference, n (%) 4 (17.4)
Resection specimen
Horizontal diameter, median (range) (mm) 70 (43-110)
Vertical diameter, median (range) (mm) 45 (20-65)
Histopathological diagnosis
Adenocarcinoma, n (%) 23 (100)
Single lesion, n (%) 16 (69.6%)
Diameter of single lesion; median
(range) (mm)
40 (10-60)
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steroid prophylaxis was completed. In contrast, the stricture
rate was significantly higher in the CR group (100% vs.
5.3%; p < 0 001). None of the patients developed infections
or other side effects during steroid treatment. Three patients
had concomitant type 2 diabetes mellitus (DM) and used oral
antidiabetics at the time of ESD. Adjustment of the antidia-
betic medication was not needed in any of them. None of
the patients without DM at the time of ESD developed DM
during steroid treatment.
Figure 3 shows examples of different courses after exten-
sive ESD.
3.4. Other Complications. The bleeding rate was 4.3% (1/23).
The patient presented with hematemesis 20 hours after cir-
cumferential ESD, and a small nonbleeding vessel was treated
with endoscopic clip application. Blood transfusion was not
indicated. No perforation- or procedure-related mortality
was observed.
3.5. Follow-Up. In eight patients, complete elimination of BE
was achieved with ESD. In one patient, a small metachronous
mucosal cancer (diameter 10mm) was resected with EMR six
months after ESD, and residual Barrett’s was ablated using
radiofrequency ablation (RFA) another three months later.
One patient, who had developed stricture after circumferen-
tial ESD, underwent repeated EBD for 6 months and refused
RFA afterwards. Metachronous mucosal cancer (diameter
8mm) was detected close to the stricture 20 months after
ESD and repeated ESD was performed. Residual nonneoplas-
tic Barrett’s was treated with radiofrequency ablation in two
patients, with APC in another three and with a combination
of RFA and APC in another two patients.
None of the patients who received ablative therapies
developed a stricture after ablation. One patient died six
months after ESD because of metastatic renal cell carci-
noma. Another patient died 12 months after ESD because
of multiple myeloma. Median follow-up was 21 months
(range 3-54).
4. Discussion
If ER exceeds 75% of the esophageal circumference, the risk
for postinterventional stricture is reported to be as high as
Patients undergoing oral steroid treatment after ESD for Barrett´s neoplasia
(resection ulcer ≥ 75% of esophageal circumference)
n = 23
Resection ulcer 100% n = 4 
First control endoscopy performed n = 21
Median on day 17 (range 10-27) 
Steroids continued n = 18
Standard dosage tapering n = 14
Tapering delayed n = 2
Tapering accelerated n = 2
EBD n = 5
Individualized EBD regimen
Second control endoscopy performed
prior to cessation of steroid n = 10
Median on day 46 (range 39-66) 
Standard dosage tapering n = 8
Tapering delayed n = 2
Duration of steroid (cumulative dose)
8 weeks (1365 mg) n = 7
10 weeks (1435 mg) n = 2
9 weeks (1610mg) n = 1
Cessation of steroid without second 
control endoscopy n = 8
Duration of steroid (cumulative dose)
8 weeks (1365 mg) n = 5
9 weeks (1400 mg) n = 1
7 weeks (1190 mg) n = 2
Routine control endoscopy 3-6 months after ESD n = 18
Stricture n = 0/18 (0%)









Resection ulcer 75-99% n = 19
Figure 2: Clinical course of patients receiving oral prednisolone prophylaxis. EBD: endoscopic balloon dilatation. ∗The patient with the
stricture had stopped steroid treatment without reasons and without side effects.
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66-100% [13–15]. Today, orally administered or locally
injected steroids are first-line treatment options for stricture
prevention [14, 15]. These techniques have been shown to
reduce but not to eliminate the stricture risk, and the ideal
treatment modality for stricture prevention remains unde-
fined. Available data, published mainly by Asian authors,
are restricted to ESD of superficial SCCs. In contrast, in
Western countries, early SCC is rare and EAC arising within
BE is the predominant indication for esophageal ER. EMR is
the endoscopic resection method of choice for small Barrett’s
neoplasia and rarely causes strictures. Pech et al. reported
12 strictures in 1000 EMRs for early EAC [16]. ESD can
be considered in lesions exceeding 15mm, poor-lifting
lesions, and lesions at risk for submucosal invasion [2].
Following this strategy, resections exceeding three quarters
of the esophageal circumference are infrequent but unavoid-
able in some cases with large or multifocal neoplasia. In our
study, 27/197 resections exceeded three quarters of the
circumference (13.7%) and four resections were performed
circumferentially (2.0%).
In 2015, we published our first data on ESD in early
esophageal cancer which included nine EAC resections
exceeding 75% of the circumference [6]. In the first six
patients, prophylactic EBD was performed. Stricture devel-
oped in five of them (83.3%) and further EBD was required.
During the later study period, three patients received a
fixed-dose 8-week oral steroid prophylaxis according to the




Figure 3: Examples for ESD and stricture prevention in large Barrett’s neoplasia. (a) Early adenocarcinoma 40mm in diameter within BE
C7M8. (b) Resection ulcer after ESD involving 80% of the circumference. (c) First control endoscopy on d16 after ESD (prednisolone dose
30mg): rapid reepithelialization, no stricture, mild dysphagia, and standard steroid tapering. (d) Second control endoscopy on d43 after
ESD (prednisolone dose 10mg): complete ulcer healing without stricture, standard steroid tapering (duration 8 weeks). (e) Multifocal
early adenocarcinoma within BE C4M6. (f) Resection ulcer after ESD involving 90% of the circumference. (g) First control endoscopy
on d12 after ESD (prednisolone dose 40mg): no rapid reepithelialization, no stricture, no dysphagia, and standard steroid tapering.
(h) Second control endoscopy on d47 after ESD (prednisolone dose 10mg): residual ulcer without narrowing of the lumen.
Prolongation of steroid tapering (duration 10 weeks). (i) Endoscopy on day 80 after ESD: complete ulcer healing without stricture.
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followed by a weekly reduction of 5mg). However, two of
them (66.7%) developed dysphagia during the steroid
tapering period and EBD was required. In 2011, Yamaguchi
et al. had reported a stricture rate of 5.3% after oral steroid
prophylaxis for ESD exceeding three quarters of the esoph-
ageal circumference [8]. Isomoto et al. reported a 50%
stricture rate after circumferential ESD using the same
regimen [9]. In both studies, a fixed-dose prednisolone
regimen was used after ESD for SCC without routine
control endoscopies (starting with 30mg daily and taper-
ing 30/30/25/25/20/15/10/5mg weekly over eight weeks).
Kataoka et al. described a 17.6% stricture rate for a shortened
prednisolone regimen (starting with 30mg daily and weekly
tapering 30/20/10mg over three weeks) [10]. So far, only
one retrospective study using steroids after EMR in BE is
available. Ratone et al. reported a 13% stricture rate using
Yamaguchi’s regime in 31 patients. However, he included
resection ulcers exceeding 50% that makes interpretation of
the data difficult [17]. Today, local injection of triamcinolone
into the resection ulcer immediately after ESD is the pre-
ferred treatment strategy in Asia. Local injection is preferred
in order to avoid potential side effects of systemic steroid
treatment. Hanaoka et al. could reach a 10% stricture rate
after injecting 100mg triamcinolone in the ESD ulcer (one
injection, fixed dose) while Hashimoto et al. reported a 19%
stricture rate after repeated triamcinolone injection (days 3,
7, and 10; dose 18-62mg) [11, 12]. A Japanese prospective
randomized control trial is ongoing to compare systemic
prednisolone therapy (Yamaguchi’s regime) and local triam-
cinolone injection (Hanaoka’s regime) [18]. The results are
awaited and the ideal treatment regime remains undefined
today, especially in Barrett’s resections.
During our first study, we had seen different courses of
ulcer healing and stricture development during routine
endoscopies in patients undergoing prophylactic EBD [6].
We proposed that the stricture risk could be minimized when
the individual scarring process would be taken into account
for tapering the steroid dose and when epithelialization of
the resection area would be completed before stopping the
steroids. Taking these considerations into account, we
decided to use a steroid regimen with a higher starting dose
(prednisolone 50mg) and individualized tapering according
to the individual ulcer healing process (assessed endoscopi-
cally during the first tapering period and before stopping
the steroids). Using this strategy, we could avoid strictures
in all patients with NCR. 95% of our patients underwent a
first control endoscopy 2-3 weeks after ESD, and the steroid
tapering was modified in 21% according to different courses
of ulcer healing. It remains speculative if the higher steroid
dose or the endoscopy-based individualization of the taper-
ing regimen has influenced the stricture development. In
particular, the role of the second control endoscopy which
was not performed in most patients seems questionable.
In contrast to patients with NCR, all patients with CR
developed a symptomatic stricture within the first 2-3 weeks
and repeated EBD was required. The stricture risk after CR
has been addressed in Asian publications on ESD of SCCs.
Hanaoka et al. described a stricture in 11/12 patients treated
with local triamcinolone and up to 40 sessions of EBD were
required. CR was an independent risk factor for stricture in
his study (adjusted OR 19.77; 95% CI 4.67-8.72) [19].
Recently, Iizuka et al. reported a modified oral steroid regi-
men starting with 30mg prednisolone and reducing the daily
dose by 5mg every three weeks (resulting in a prolonged
treatment duration of 18 weeks). However, 10/11 patients
had received additional local triamcinolone injections. The
stricture rate after CR of SCCs was 36.4% and significantly
lower compared to 82% after using Yamaguchi’s regimen
over 8 weeks [19]. Potential side effects of oral steroid pro-
phylaxis regimens are feared but discussed controversially.
Using a fixed-dose oral regimen over 8 weeks, Yamaguchi
et al. did not report any side effects in 22 patients [8]. In
contrast, Iizuka et al. reported three infections when nine
patients were treated with the same regimen (pneumonia,
oral herpes infection) [19]. Ishida et al. reported a case
with severe disseminated nocardiosis during oral steroid
prophylaxis [20]. In our study, we could confirm Yamagu-
chi’s data and did not find infectious complications or
other serious side effects in any patient. Patients should
be informed about potential side effects and should be
monitored carefully during the steroid treatment. Sufficient
data not only on stricture prevention but also on steroid
side effects are awaited from the ongoing Japanese multi-
center study [18].
Today, it remains unclear if the risk of postinterventional
stricture development is different for SCC and EAC and if
Asian results are transferable to Western countries where
EACs represent the vast majority of esophageal lesions.
Limitations of the study are the retrospective design, the
small patient number, and the missing control group. Some
patients did not undergo the second control endoscopy
which is another limitation. Randomized controlled trials
comparing different strategies are needed to define the ideal
prevention strategy after extensive ER in neoplastic BE.
5. Conclusion
In our small study, oral steroid administration with an
endoscopy-based individualization of dosage and treatment
duration was sufficient to prevent strictures after extensive
but noncircumferential ER of EAC. The stricture rate was
lower compared to all previous studies reporting on steroid
prophylaxis [14, 15]. In contrast, strictures could not be
avoided after circumferential resection. After circumferential
resection of neoplastic Barrett’s esophagus, EBD should be
started early. Circumferential extension of EAC is a very rare
scenario and CR should be restricted to these rare lesions.
The strategy for stricture prevention after CR needs to be
further improved.
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